TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of a Multi-dose Regimen of Mebendazole Against Hookworm in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent signed by parents and/or caregiver; and oral assent by participant.~* Able and willing to be examined by a study physician at the beginning of the study.~* Able and willing to provide two stool samples at the beginning (baseline) and approximately three weeks after treatment (follow-up).~* Positive for hookworm eggs in the stool (≥ 100 EPG and at least two Kato-Katz thick smears slides with more than one hookworm egg).~* Absence of major systemic illnesses, e.g. diabetes, severe anemia (HB\<8.0 g/l) as assessed by a medical doctor at school, upon initial clinical assessment.~* No known or reported history of chronical illness as cancer, diabetes, chronic heart, liver or renal disease.~* No recent anthelminthic treatment (within past 4 weeks). No known allergy to study medications (mebendazole and albendazole).~Exclusion Criteria:~No written informed consent by parents and/or caregiver; no oral assent by participant.~* Menarche, based on self-report~* Presence of major systemic illnesses, e.g. diabetes, severe anemia (HB\<8.0 g/l) as assessed by a medical doctor, upon initial clinical assessment.~* History of acute or severe chronic disease.~* Recent use of anthelminthic drug (within past 4 weeks).~* Attending other clinical trials during the study.~* Negative diagnostic result for hookworm eggs in the stool (\< 100 EPG (total of the four slides) and/or only one Kato-Katz thick smear slide with more than one hookworm egg).

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Single dose of mebendazole (Type: ACTIVE_COMPARATOR): In day 1 each child in this treatment arm will receive a 500 mg tablet of mebendazole plus one 100 mg placebo tablet in the morning. In the afternoon of day 1 they will only receive the placebo. In day 2 and 3 each child will receive one placebo twice a day (in the morning and in the evening)
- Multiple dose of mebendazole (Type: ACTIVE_COMPARATOR): In day 1 each child in this treatment arm will receive a 100 mg tablet of mebendazole plus one 500 mg placebo tablet in the morning. In the afternoon of day 1 they will only receive the 100 mg tablet of mebendazole. In day 2 and 3 each child will receive one 100 mg tablet of mebendazole twice a day (in the morning and in the evening).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of EpiCept™ NP-1 Topical Cream vs. Oral Gabapentin in Postherpetic Neuralgia (PHN)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with pain for ≥ 3 months following onset of a herpes zoster rash~Exclusion Criteria:~* Clinically significant intercurrent illness (e.g., endocrine, cardiac, hepatic, renal, neurologic, hematologic, skeletal) that the investigator determines could interfere with the efficacy or safety assessments.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- amitriptyline 4% ketamine 2% cream, placebo capsules (Type: ACTIVE_COMPARATOR): Np-1 cream and placebo gabapentin
- gabapentin capsules, placebo cream (Type: ACTIVE_COMPARATOR): gabapentin caps and placebo cream
- placebo cream and capsules (Type: PLACEBO_COMPARATOR): placebo cream and capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Vildagliptin as add-on Therapy to Insulin in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of T2DM~* On a stable dose of insulin as defined by the protocol~* On a stable does of metformin (if applicable) as defined by the protocol~* Age 18 to 80 years~* HbA1c of 7.5 to 11.0%~* Body Mass Index (BMI) 22 to 40 kg/m2~Exclusion Criteria:~* Type 1 diabetes~* Short-acting or rapid-acting insulin~* Pregnancy or lactation~* Evidence of serious diabetic complications~* Evidence of serious cardiovascular complications~* Laboratory value abnormalities as defined by the protocol~* Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Vildagliptin (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Prometic Plasminogen IV Infusion in Subjects With Hypoplasminogenemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is a male or female between the ages of 2 and 80 years (inclusive), is able to provide informed consent or assent, and agrees to use contraceptive methods during the study (unless documented as biologically or surgically sterile or has not reached reproductive age).~* Subject has documented history of hypoplasminogenemia and has plasminogen activity level ≤ 45%.~* Subject had a documented history of lesions and symptoms consistent with a diagnosis of congenital plasminogen deficiency.~* Subject has documented vaccination to hepatitis A virus (HAV) and hepatitis B virus (HBV), or has received the first dose of HAV and HBV vaccine prior to the first dose of IMP and is scheduled to receive the second vaccine dose.~Exclusion Criteria:~* Subject has uncontrolled hypertension; clinical or laboratory evidence of an intercurrent infection; a malignancy within 3 years, except for basal or squamous cell skin cancer; a psychiatric disorder; chronic or acute clinically significant inter-current illness; or evidence of renal and hepatic dysfunction.~* Subject is pregnant or lactating~* Subject has a history of anaphylactic reactions to blood or blood products that may interfere with participation in study in the opinion of the investigator.~* Subject is a previous organ transplant recipient; has received exogenous plasminogen within 2 weeks of the screening; has a history of anaphylactic reactions to blood or blood products; or has received another IRB-approved interventional clinical trial of a drug, biologic, or device within 30 days before the first dose of the IMP.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 6.6 mg/kg Plasminogen (Human) Intravenous (Type: EXPERIMENTAL): 6.6 mg/kg Plasminogen (Human) Intravenous given every 2 to 4 days by a 10- to 30-minute intravenous infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Cooling Sensation and Consumer Liking of a Skin Disinfectant Spray

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participants in good health with healthy and intact skin on the test area~* Age 18-60 years~Exclusion Criteria:~* Pregnancy or breast-feeding~* Allergy/Intolerance~* Participants currently taking any topical or systemic treatments that may interfere with or mask the test results~* Participants who have taken any topical anti-inflammation treatment in the application area in past 2 months~* Participants who are vulnerable to any intervention~* Damaged skin close to test site, active skin disorders, any visible skin disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Prototype disinfectant spray formulation (Type: EXPERIMENTAL): 0.13% w/w Benzalkonium Chloride (BAC) and 1% Menthone Glycerin Acetal (MGA). After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
- Reference product (Type: ACTIVE_COMPARATOR): 0.13% w/w BAC. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
- Negative control (Type: PLACEBO_COMPARATOR): 0.9% w/v sodium chloride solution. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Articaine Versus Lidocaine as Supplemental Infiltration in Inflamed Molars

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients~* irreversible pulpitis in mandibular molar~Exclusion Criteria:~* below 18 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IANB Articaine (Type: ACTIVE_COMPARATOR): IANB Articaine: Inferior alveolar nerve block (IANB) anesthesia with articaine local anesthetic.
- SUP Articaine (Type: ACTIVE_COMPARATOR): SUP Articaine: Supplemental buccal anesthesia (SUP) with articaine local anesthetic after unsuccessful IANB.
- SUP Lidocaine (Type: ACTIVE_COMPARATOR): SUP Lidocaine: Supplemental buccal anesthesia (SUP) with lidocaine local anesthetic after unsuccessful IANB.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Enhancing Equitable and Effective (E-3) Post Traumatic Stress Disorder (PTSD) Disability Assessment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Veterans referred to VHA for an Initial PTSD Compensation and Pension Examination~2. Informed consent~Exclusion Criteria:~1. Mentally impaired, not able to give informed consent~2. English speaking

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- CAPS/WHODAS (Type: EXPERIMENTAL): PTSD assessed using Clinical Assessment of PTSD Symptoms (CAPS) and WHODAS functional impairment structured evidence-based interview
- Nonstructured Interview (Type: ACTIVE_COMPARATOR): Usual clinical interview to assess PTSD, without CAPS or WHODAS

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Diabetes Assistant (DiAs) Control-to-Range (CTR) Nocturnal Closed-Loop Camp Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinical diagnosis of type 1 diabetes and using daily insulin therapy for at least one year and a Medtronic, Animas or Tandem insulin infusion pump for at least 3 months~2. The diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide levels and antibody determinations are not required.~3. Age 10.0 - 35 years~4. Willingness to use a Sure-T or Contact Detach infusion set while at camp~Exclusion Criteria:~1. Diabetic ketoacidosis in the past month~2. Hypoglycemic seizure or loss of consciousness in the past 3 months~3. History of seizure disorder (except for hypoglycemic seizure)~4. Using an OmniPod insulin infusion pump~5. History of any heart disease including coronary artery disease, heart failure, or arrhythmias~6. Cystic fibrosis~7. Current use of oral/inhaled glucocorticoids, beta-blockers or other medications, which in the judgment of the investigator would be a contraindication to participation in the study.~8. History of ongoing renal disease (other than microalbuminuria).~9. Insulin pump users who supplement with injected intermediate or long acting insulin.~10. Subjects who take other anti-diabetic medications other than insulin..~11. Medical or psychiatric condition that in the judgment of the investigator might interfere with the completion of the protocol such as:~12. Inpatient psychiatric treatment in the past 6 months~13. Uncontrolled adrenal disorder~14. Abuse of alcohol~15. Pregnancy (verbal denial of pregnancy obtained with telephone informed consent, pregnancy test performed at camp before study devices are assigned).~16. Sexually active females who do not practice acceptable contraceptive methods to prevent pregnancy.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Closed-Loop Control with DiAs System (Type: EXPERIMENTAL): Subjects will use the Diabetes Assistant (DiAs) and will wear a Tandem t:slim insulin pump and a Dexcom G4 Platinum sensor with active low and high sensor glucose alarms. Subjects will be remotely monitored throughout the night in real time.
- Control Group, Sensor-Augmented Pump Therapy (Type: PLACEBO_COMPARATOR): Subjects will wear a Tandem t:slim insulin pump and a Dexcom G4 Platinum sensor with active low and high sensor glucose alarms. They will not use the Diabetes Assistant (DiAs) nor have remote monitoring.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Caffeine and Intermittent Claudication

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* men and women \> 40 years~* history of IC of the lower extremities, Fontaine II~* ankle-brachial index (ABI)\> 0.9 (subjects who are referred for a revasularizarition procedure)~Exclusion Criteria:~* dementia~* diabetes~* illness or reason to be unable to participate, f.ex. general weakness, amputation or arthritis~* acute illness, f.ex. inflammation, unstable angina~* other reasons which contraindicate participation/treadmill exercise~* intake of Trental and/or Teofyllamin~* weight \> 100kg

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Galantamine on Cognition

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age range of 18-64 (confirmed by drivers license or other form of identification)~* the presence of 3 or more SSP symptoms (at least 2 of the SSP symptoms will be negative symptoms as defined by the schizoid traits)~* the presence of visuospatial working memory impairment as defined by error in the oculomotor delayed response (ODR) task of more than 0.5 SD above the mean values in healthy control subjects~* relative of an individual with schizophrenia, schizoaffective disorder, or schizophreniform disorder~* able to provide written informed consent (ESC score 10 or above)~Exclusion Criteria:~* subjects meeting criteria for a life-time diagnosis of any one of the DSM IV, Axis I psychotic disorders (exceptions being a single past episode of major depressive disorder with psychotic features or psychotic symptoms associated with substance abuse with the substance abuse ending 6-months prior to study participation) (this is for the SSP recruitment)~* subjects meeting DSM-IV criteria for current alcohol or substance dependence (other than nicotine) within the last 6 months or DSM-IV criteria for alcohol or substance abuse (other than nicotine) within the last month~* medical conditions that preclude participation in drug trials or assessments of outcome measures (including significant brain, cardiac, liver, lung, endocrinological or metabolic disorders)~* received any investigational drug in the preceding four weeks~* pregnant or of childbearing age and not using a medically approved form of birth control

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Galantamine, then Placebo (Type: EXPERIMENTAL): Participants took lead-in 3 days of 4mg/ twice a day of galantamine followed by 8 mg on the 4th day, the day of testing. Then, after a period of at least one month, participants took lead-in 3 days of 4mg/ twice a day of placebo followed by 8 mg on the 4th day, the day of testing.
- Placebo, then Galantamine (Type: EXPERIMENTAL): Participants took lead-in 3 days of 4mg/ twice a day of placebo followed by 8 mg on the 4th day, the day of testing. Then, after a period of at least one month, participants took lead-in 3 days of 4mg/ twice a day of galantamine followed by 8 mg on the 4th day, the day of testing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare the Use of Ferric Carboxymaltose With Placebo in Patients With Chronic Heart Failure and Iron Deficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Iron deficient subjects with stable chronic heart failure (CHF) (NYHA II-III) on optimal background therapy for CHF~* Reduced left ventricular ejection fraction~* Capable of completing 6 minute walk test~* At least 18 years of age and with written informed consent prior to any study specific procedures~Exclusion Criteria:~* Erythropoietin stimulating agent (ESA) use, IV iron therapy and/or blood transfusion in previous 6 weeks prior to randomisation~* Exercise training program(s) in the 3 months prior to screening or planned in the next 6 months~* Chronic liver disease and/or elevated liver enzymes~* Vitamin B12 and/or serum folate deficiency~* Subject is not using adequate contraceptive precautions during the study~* Body weight ≤ 35 kg~* No other significant cardiac or general disorders that would compromise the ability to give informed consent and/or comply with study procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ferinject (ferric carboxymaltose) (Type: EXPERIMENTAL): None
- Placebo (saline) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~The subject must have:~* Her most recent surgical and - if available - histological diagnosis of pelvic endometriosis up to 10 years before screening.~* Moderate to severe endometriosis-associated pain during the screening period.~* Regular menstrual cycles.~* BMI ≥ 18 kg/m2 at the screening visit. -~Exclusion Criteria:~The subject will be excluded if she:~* Is pregnant or breast feeding or is planning a pregnancy within the duration of the treatment period of the study.~* Is less than 6 months postpartum or 3 months postabortion/ miscarriage at the time of entry into the screening period.~* Has had a surgical history of any major abdominal surgery within 6 months or any interventional surgery for endometriosis performed within a period of 2 months before screening.~* Did not respond to prior treatment with GnRH agonists or GnRH antagonists for endometriosis.~* Has a history of, or known, osteoporosis or other metabolic bone disease.~* Has chronic pelvic pain that is not caused by endometriosis and requires chronic analgesic or other chronic therapy which would interfere with the assessment of endometriosis-associated pain.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: f

Study Arms:
- Linzagolix 75 mg (Type: EXPERIMENTAL): None
- Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg) (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Use of Antiseptic Solution for Vaginal Wash Before Cesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women with gestation between 34 and 41 6/7 weeks.~* Premature rupture of membranes (\> 6 hours).~* Use of prophylactic antibiotic 1 hour previous to cesarean section.~Exclusion Criteria:~* Any source of infection diagnosed previous to surgery.~* Fever of unknown origin previous to surgery.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clorhexidine (Type: EXPERIMENTAL): Vaginal wash with clorhexidine solution
- Saline solution (Type: PLACEBO_COMPARATOR): Vaginal wash with saline solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete